Intercept Pharmaceuticals (ICPT) Competitor Comparison
We are evaluating the key criteria listed to compare Intercept Pharmaceuticals (ICPT) against its competitors in the Biotechnology industry.
Market Capitalization
139 / 368Gross Profits
23 / 278Total Revenue
36 / 300EBITDA
146 / 337Free Cashflow
193 / 352Quick Ratio
223 / 357Earnings per Share
139 / 359Dividend yield
0 / 6Total Cash
101 / 358Performance 3 years
164 / 368Performance 5 years
233 / 368Performance 10 years
163 / 368Linearity 3 years
114 / 368Linearity 5 years
231 / 368Linearity 10 years
44 / 368Total Rank
164 / 368Dividend Rank
168 / 368Valuation Rank
156 / 368Piotroski Rank
134 / 368Muliplier Rank
32 / 368Free Cashflow - ICPT ranking 193 / 352
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.